Anti-CREBBP antibody (ab10490)
Key features and details
- Rabbit polyclonal to CREBBP
- Suitable for: IP, IHC-P, WB
- Reacts with: Human
- Isotype: IgG
Get better batch-to-batch reproducibility with a recombinant antibody
- Research with confidence – consistent and reproducible results with every batch
- Long-term and scalable supply – powered by recombinant technology for fast production
- Success from the first experiment – confirmed specificity through extensive validation
- Ethical standards compliant – production is animal-free
Overview
-
Product name
Anti-CREBBP antibody
See all CREBBP primary antibodies -
Description
Rabbit polyclonal to CREBBP -
Host species
Rabbit -
Tested applications
Suitable for: IP, IHC-P, WBmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Chimpanzee, Rhesus monkey, Gorilla, Orangutan -
Immunogen
-
Positive control
- WB: HeLa whole cell lysate IHC-P: human prostate carcinoma tissue
-
General notes
Cyclic AMP-responsive enhancer binding protein (CREB) binding protein (CBP) and p300 are closely related transcriptional coactivators that have been shown to directly interact with many different DNA-binding transcription factors including nuclear hormone receptors, CREB (cyclic AMP-responsive enhancer binding protein), c-Fos, c-Jun/v-Jun, c-Myb/v-Myb, TFIIB and MyoD.Both CBP and p300 have been shown to display histone acetyltransferase (HAT) activity, capable of acetylating all four core histone particles in nucleosomes.As a result of HAT activity, it has been suggested CBP and p300 may play a direct role in activating chromatin for transcription.Single point mutations in CBP have been proposed as causative factors in the developmental abnormalities of Rubinstein-Taybi syndrome (RTS).Although both CBP and p300 appear to function similarly, the inability of p300 to rescue CBP malfunction iRTS suggests intrinsic functional differences between CBP and p300.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7
Preservative: 0.1% Sodium azide
Constituents: 0.021% PBS, 1.764% Sodium citrate, 1.815% Tris -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Purification notes
Antibodies were affinity purified using the peptide immobilized on solid support. -
Primary antibody notes
Cyclic AMP-responsive enhancer binding protein (CREB) binding protein (CBP) and p300 are closely related transcriptional coactivators that have been shown to directly interact with many different DNA-binding transcription factors including nuclear hormone receptors, CREB (cyclic AMP-responsive enhancer binding protein), c-Fos, c-Jun/v-Jun, c-Myb/v-Myb, TFIIB and MyoD.Both CBP and p300 have been shown to display histone acetyltransferase (HAT) activity, capable of acetylating all four core histone particles in nucleosomes.As a result of HAT activity, it has been suggested CBP and p300 may play a direct role in activating chromatin for transcription.Single point mutations in CBP have been proposed as causative factors in the developmental abnormalities of Rubinstein-Taybi syndrome (RTS).Although both CBP and p300 appear to function similarly, the inability of p300 to rescue CBP malfunction iRTS suggests intrinsic functional differences between CBP and p300. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
ChIP Related Products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab10490 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IP |
Use at 1-4 µg/mg of lysate.
|
|
IHC-P |
1/200 - 1/1000. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
|
|
WB |
1/1000 - 1/25000. Predicted molecular weight: 265 kDa.
|
Notes |
---|
IP
Use at 1-4 µg/mg of lysate. |
IHC-P
1/200 - 1/1000. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
WB
1/1000 - 1/25000. Predicted molecular weight: 265 kDa. |
Target
-
Function
Acetylates histones, giving a specific tag for transcriptional activation. Also acetylates non-histone proteins, like NCOA3 coactivator. Binds specifically to phosphorylated CREB and enhances its transcriptional activity toward cAMP-responsive genes. Acts as a coactivator of ALX1 in the presence of EP300. -
Involvement in disease
Note=Chromosomal aberrations involving CREBBP may be a cause of acute myeloid leukemias. Translocation t(8;16)(p11;p13) with MYST3/MOZ; translocation t(11;16)(q23;p13.3) with MLL/HRX; translocation t(10;16)(q22;p13) with MYST4/MORF. MYST3-CREBBP may induce leukemia by inhibiting RUNX1-mediated transcription.
Defects in CREBBP are a cause of Rubinstein-Taybi syndrome type 1 (RSTS1) [MIM:180849]. RSTS1 is an autosomal dominant disorder characterized by craniofacial abnormalities, broad thumbs, broad big toes, mental retardation and a propensity for development of malignancies. -
Sequence similarities
Contains 1 bromo domain.
Contains 1 KIX domain.
Contains 2 TAZ-type zinc fingers.
Contains 1 ZZ-type zinc finger. -
Domain
The KIX domain mediates binding to HIV-1 Tat. -
Post-translational
modificationsMethylation of the KIX domain by CARM1 blocks association with CREB. This results in the blockade of CREB signaling, and in activation of apoptotic response.
Phosphorylated upon DNA damage, probably by ATM or ATR.
Sumoylation negatively regulates transcriptional activity via the recruitment of DAAX. -
Cellular localization
Cytoplasm. Nucleus. Recruited to nuclear bodies by SS18L1/CREST. In the presence of ALX1 relocalizes from the cytoplasm to the nucleus. - Information by UniProt
-
Database links
- Entrez Gene: 1387 Human
- Entrez Gene: 12914 Mouse
- Omim: 600140 Human
- SwissProt: Q92793 Human
- SwissProt: P45481 Mouse
- Unigene: 459759 Human
- Unigene: 132238 Mouse
- Unigene: 392384 Mouse
-
Alternative names
- CBP antibody
- CBP_HUMAN antibody
- CREB binding protein antibody
see all
Images
-
All lanes : Anti-CREBBP antibody (ab10490) at 0.4 µg/ml
Lane 1 : HeLa (human epithelial cell line from cervix adenocarcinoma) whole cell lysate at 50 µg
Lane 2 : HeLa whole cell lysate at 15 µg
Lane 3 : HeLa whole cell lysate at 5 µg
Predicted band size: 265 kDa
Exposure time: 3 minutesDetected by chemiluminescence.
-
ab10490 immunoprecipitating CREBBP at 6 µg/ml lysate.
Lane 1: Anti-CREBBP antibody ab10489 in HeLa whole cell extract (1 mg per IP reaction; 20% of IP loaded).
Lane 2: Anti-CREBBP antibody ab10490 in HeLa whole cell extract (1 mg per IP reaction; 20% of IP loaded).
Lane 3: IgG control.
For blotting immunoprecipitated CREBBP, ab10490 was used at 1 µg/mL.
Detection: Chemiluminescence with an exposure time of 30 seconds.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human prostate carcinoma tissue labelling CREBBP with ab10490 at 1/500 (2µg/ml). Detection: DAB.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab10490 has not yet been referenced specifically in any publications.